Table III.

Strategies to reverse non-small cell lung cancer drug resistance.

First author, year	Factor	Mechanisms	Resistant to	Inhibitor of	(Refs.)
Shien et al, 2017	IL-6	OSMRs/JAK1/STAT3	Chemotherapy	JAK1	(119)
Rotow et al, 2017	HGF	HGF/ERK	Targeted therapy	HGF	(2)
Tao et al, 2016	IL-11	IL-11R/STAT3	Chemotherapy	STAT3	(118)
Zhang et al, 2018	IGF	IGF1R/AKT/Sox2/P-GP	Chemotherapy	IGF2	(96)
Wang et al, 2019	ANXA3	ANXA3/JNK	Chemotherapy	JNK	(116)
Wei et al, 2020	GGT5		Chemotherapy	GGT5	(117)
Najafi et al, 2019; Rebelo et al, 2018	MMPs	Degradation of the ECM	Chemotherapy/immunotherapy		(82,121)

OSMRs, oncostatin-M; JAK1, Janus kinase1; STAT3, signal transducer and activator of transcription 3; HGF, hepatocyte growth factor; IGF, insulin-like growth factor; IGF1R, insulin-like growth factor receptor-1; P-GP, P-glycoprotein; ANXA3, Annexin A3; GGT5, γ-glutamyl transferase 5; MMP, matrix metalloproteinase; ECM, extracellular matrix.